Home » Topics » Disease categories and therapies » Gastrointestinal

Gastrointestinal
RSS

TLR2 antagonists emerge from Eisai R&D

Aug. 24, 2005

New anti-HCV agents prepared and tested

Aug. 22, 2005

Migenix cleared to begin phase IIb study of MX-3253 in Canada

Aug. 18, 2005

Vaqta approved for children as young as 12 months of age

Aug. 18, 2005

Dosing begins in phase I study of GS-9132 for HCV

Aug. 18, 2005

Dosing completed in phase II study of HepeX-B

Aug. 11, 2005

New phase I antiviral study of Tarvacin for HCV

Aug. 10, 2005

Genelabs advances two nonnucleoside compounds for HCV

Aug. 10, 2005

Solvay and Mayo Clinic collaborate on gastrointestinal motility disorders

Aug. 10, 2005

A phase III study confirms the efficacy of telbivudine in compensated chronic hepatitis B

Aug. 4, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...